Database for Interstitial Lung Disease
Clinical Database for the Early Recognition of Pulmonary Parenchymal Involvement in Patients With Systemic Diseases Bearing a Risk for Interstitial Lung Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Gabor Kovacs, MD
- Phone Number: 12183 +43-316-385
- Email: gabor.kovacs@klinikum-graz.at
Study Locations
-
-
-
Graz, Austria, 8036
- Recruiting
- Medical University of Graz, Department of Internal Medicine, Division of Pulmonology
-
Contact:
- Gabor Kovacs, MD
- Phone Number: +43-316-385-80748
- Email: gabor.kovacs@klinikum-graz.at
-
Contact:
- Katarina Zeder, MD
- Email: katarina.zeder@medunigraz.at
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age: ≥ 18 years
- patients with a known systemic disease bearing a risk for ILD
- signed informed consent (for prospective part)
Exclusion Criteria:
- Age < 18 years
- comorbidities severely limiting life-expectancy (e.g. severe cardiovascular conditions, malignant disease)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
prospective patient cohort
patients who will undergo the prospective ILD Screening algorithm
|
assessment of interstitial lung disease using chest CT
|
|
retrospective patient cohort
patients with diagnosed ILD
|
assessment of interstitial lung disease using chest CT
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
DLCO%pred (carbon monoxide diffusing capacity) at time of ILD diagnosis
Time Frame: 5 years
|
The investigators aim to assess DLCO% pred at time of ILD diagnosis in patients undergoing a ILD Screening algorithm and compare to the retrospective patient cohort with diagnosed ILD and the DLCO%pred at time of ILD diagnosis
|
5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
FVC%pred (Forced vital capacity) at time of ILD diagnosis
Time Frame: 5 years
|
The investigators aim to assess FVC% pred at time of ILD diagnosis in patients undergoing a ILD Screening algorithm and compare to the retrospective patient cohort with diagnosed ILD and the FVC%pred at time of ILD diagnosis
|
5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 33-023 ex 20/21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.